2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenI believe that the huge layer of fat, of employees, still needs to be trimmed, and more AI incorporated. The director choice was also unfortunate. We have to go all the way back to Juli/August 2021 for the same share price, it's poorly managed.
You're confusing things. Management does not control the stock price but the profit in the company. And that has only gone one way and that is up. That investors then don't like the way it is presented is the investors' problem. Try to compare the profit in 2021 with today and then ask yourself again who is managing poorly. Management or the investors.
·2 t sittenI believe that Novo Nordisk at around price 300 is very interesting as a long-term buy. The stock has fallen sharply from its peak, while Novo still has a strong position in diabetes and obesity treatment. In Q2 2026, sales grew 7 % and operating profit 11 % measured at constant exchange rates, and the company simultaneously raised its expectations for 2026. Yes, competition from especially Eli Lilly is real, and Novo has also had disappointments in the pipeline. But I believe the market is currently focusing heavily on the immediate problems and less on Novo as a company over the next 5-10 years. For me, a purchase around price 300 is therefore not about Novo necessarily rising quickly. It's about me believing that you get a world-class company at a much more attractive price than before – with strong products, a large global patient base, and continued opportunities in obesity and diabetes. I am not buying Novo because the risk is gone. I am buying because, in my opinion, the price already reflects a great deal of the pessimism. Novo 🤞🚀📈
·2 t sittenThe company needs to release some positive news in the near future regarding something that is in the pipeline. For my part, I have restructured my portfolio and currently have no holding in the company.
5 t sittenUPDATE: Aug. 28, 2026 Twenty weeks into its launch, Eli Lilly's Foundayo has finally exceeded 40,000 in weekly prescriptions, according to IQVIA data cited by Citi. The oral GLP-1 drug posted 40,862 scripts last week, bouncing back from a small dip the week prior. Still, the drug's scripts level is no match for the roughly 57K that Novo Nordisk's Wegovy pill garnered at week 6 of its own launch. In its 33rd week of launch, the Wegovy pill booked roughly 175K scripts, slightly down from 176K, per IQVIA. The share of the oral version of semaglutide in all Wegovy obesity scripts was flat week over week at 35%. All told, across the pill and the injectable, Wegovy's weekly scripts were a little over 500K, down 0.8% sequentially. As Jefferies analysts observed in an Aug. 21 note, Wegovy has been relatively flat since the Medicare GLP-1 Bridge program began July 1. Overall, the roughly 60%-40% obesity market share split between Lilly and Novo remained stable, as Lilly's Zepbound held its ground as the most popular drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenI believe that the huge layer of fat, of employees, still needs to be trimmed, and more AI incorporated. The director choice was also unfortunate. We have to go all the way back to Juli/August 2021 for the same share price, it's poorly managed.You're confusing things. Management does not control the stock price but the profit in the company. And that has only gone one way and that is up. That investors then don't like the way it is presented is the investors' problem. Try to compare the profit in 2021 with today and then ask yourself again who is managing poorly. Management or the investors.
- ·2 t sittenI believe that Novo Nordisk at around price 300 is very interesting as a long-term buy. The stock has fallen sharply from its peak, while Novo still has a strong position in diabetes and obesity treatment. In Q2 2026, sales grew 7 % and operating profit 11 % measured at constant exchange rates, and the company simultaneously raised its expectations for 2026. Yes, competition from especially Eli Lilly is real, and Novo has also had disappointments in the pipeline. But I believe the market is currently focusing heavily on the immediate problems and less on Novo as a company over the next 5-10 years. For me, a purchase around price 300 is therefore not about Novo necessarily rising quickly. It's about me believing that you get a world-class company at a much more attractive price than before – with strong products, a large global patient base, and continued opportunities in obesity and diabetes. I am not buying Novo because the risk is gone. I am buying because, in my opinion, the price already reflects a great deal of the pessimism. Novo 🤞🚀📈
- ·2 t sittenThe company needs to release some positive news in the near future regarding something that is in the pipeline. For my part, I have restructured my portfolio and currently have no holding in the company.
- 5 t sittenUPDATE: Aug. 28, 2026 Twenty weeks into its launch, Eli Lilly's Foundayo has finally exceeded 40,000 in weekly prescriptions, according to IQVIA data cited by Citi. The oral GLP-1 drug posted 40,862 scripts last week, bouncing back from a small dip the week prior. Still, the drug's scripts level is no match for the roughly 57K that Novo Nordisk's Wegovy pill garnered at week 6 of its own launch. In its 33rd week of launch, the Wegovy pill booked roughly 175K scripts, slightly down from 176K, per IQVIA. The share of the oral version of semaglutide in all Wegovy obesity scripts was flat week over week at 35%. All told, across the pill and the injectable, Wegovy's weekly scripts were a little over 500K, down 0.8% sequentially. As Jefferies analysts observed in an Aug. 21 note, Wegovy has been relatively flat since the Medicare GLP-1 Bridge program began July 1. Overall, the roughly 60%-40% obesity market share split between Lilly and Novo remained stable, as Lilly's Zepbound held its ground as the most popular drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenI believe that the huge layer of fat, of employees, still needs to be trimmed, and more AI incorporated. The director choice was also unfortunate. We have to go all the way back to Juli/August 2021 for the same share price, it's poorly managed.You're confusing things. Management does not control the stock price but the profit in the company. And that has only gone one way and that is up. That investors then don't like the way it is presented is the investors' problem. Try to compare the profit in 2021 with today and then ask yourself again who is managing poorly. Management or the investors.
- ·2 t sittenI believe that Novo Nordisk at around price 300 is very interesting as a long-term buy. The stock has fallen sharply from its peak, while Novo still has a strong position in diabetes and obesity treatment. In Q2 2026, sales grew 7 % and operating profit 11 % measured at constant exchange rates, and the company simultaneously raised its expectations for 2026. Yes, competition from especially Eli Lilly is real, and Novo has also had disappointments in the pipeline. But I believe the market is currently focusing heavily on the immediate problems and less on Novo as a company over the next 5-10 years. For me, a purchase around price 300 is therefore not about Novo necessarily rising quickly. It's about me believing that you get a world-class company at a much more attractive price than before – with strong products, a large global patient base, and continued opportunities in obesity and diabetes. I am not buying Novo because the risk is gone. I am buying because, in my opinion, the price already reflects a great deal of the pessimism. Novo 🤞🚀📈
- ·2 t sittenThe company needs to release some positive news in the near future regarding something that is in the pipeline. For my part, I have restructured my portfolio and currently have no holding in the company.
- 5 t sittenUPDATE: Aug. 28, 2026 Twenty weeks into its launch, Eli Lilly's Foundayo has finally exceeded 40,000 in weekly prescriptions, according to IQVIA data cited by Citi. The oral GLP-1 drug posted 40,862 scripts last week, bouncing back from a small dip the week prior. Still, the drug's scripts level is no match for the roughly 57K that Novo Nordisk's Wegovy pill garnered at week 6 of its own launch. In its 33rd week of launch, the Wegovy pill booked roughly 175K scripts, slightly down from 176K, per IQVIA. The share of the oral version of semaglutide in all Wegovy obesity scripts was flat week over week at 35%. All told, across the pill and the injectable, Wegovy's weekly scripts were a little over 500K, down 0.8% sequentially. As Jefferies analysts observed in an Aug. 21 note, Wegovy has been relatively flat since the Medicare GLP-1 Bridge program began July 1. Overall, the roughly 60%-40% obesity market share split between Lilly and Novo remained stable, as Lilly's Zepbound held its ground as the most popular drug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt